Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer

Overview of attention for article published in New England Journal of Medicine, September 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (76th percentile)

Mentioned by

news: 51 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 132 X users
patent: 1 patent

facebook: 2 Facebook pages
reddit: 4 Redditors
guideline: 8 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 626 Mendeley

So far, Altmetric has seen 73 news stories from 51 outlets.

Toripalimab Plus CCRT Generates 100% ORR, But Safety Concerns Warrant Additional Research in Locally Advanced Cervical Cancer

OncLive, 16 Oct 2025

The addition of toripalimab-tpzi (Loqtorzi) to concurrent chemoradiotherapy (CCRT) led to an overall response rate (ORR) of 100…

Cervical Cancer: 5 Things to Know

Medscape, 11 Aug 2025

Cervical cancer remains a significant global health concern, ranking as the fourth most common cancer in women worldwide, with…

Cadonilimab plus chemotherapy improves survival in recurrent or metastatic cervical cancer | 2 Minute Medicine

2 Minute Medicine , 05 Dec 2024

1. Cadonilimab plus chemotherapy significantly improved progression-free survival in patients with persistent, recurrent, or…

Pembrolizumab with chemoradiotherapy improves survival in locally advanced cervical cancer | 2 Minute Medicine

2 Minute Medicine , 29 Oct 2024

1. 36-month overall survival was significantly greater in the pembrolizumab-chemoradiotherapy group compared to placebo-chemoradi…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 69 additional news stories.